



## Quick Take

### Anthera Pharmaceuticals — Outperform (1)

**ANTH: \$5.21**

### Quick Take: Q4 Spending Above Forecast; VISTA-16 And PEARL-SC On Track

February 23, 2011

#### Analysts

**Steve Scala, R.Ph., CFA**  
(617) 946-3923  
steve.scala@cowen.com

**Ian Sanderson**  
(617) 946-3922  
ian.sanderson@cowen.com

**Jean Perreault**  
(617) 946-3967  
jean.perreault@cowen.com

This morning Anthera reported Q4:10 results. Below are the key highlights:

- Operating Income of (\$12.9MM) versus our estimate of (\$10.9MM)
- R&D of \$10.9MM was \$1.9MM above our \$9MM estimate
- SG&A of \$2.1MM was \$0.6MM above our \$1.5MM forecast
- Increased spending relates to initiation of trial sites for VISTA-16, increased A-623 manufacturing activities and operational expansion of PEARL-SC, and one-time expenses associated with the mitigation and resolution of the A-623 vial cracking problem.

Updates on Anthera's clinical development program are:

- VISTA-16 site activations and enrollment are on-track for completion of the interim biomarker analysis, as **patient enrollment has exceeded the required 1,000 patient threshold. Data for the interim analysis is expected to be made available to an independent statistician within the coming weeks.** The interim analysis will examine four predefined biomarkers of cardiovascular risk (sPLA2, IL-6, CRP, and LDL-C) and one composite responder index (proportion of patients achieving LDL-4 <70 and CRP <1). Varespladib must be significantly different from placebo per a predefined algorithm to measure improvement and meet various statistical treatment effects on the required biomarkers in order for the study to continue. Subsequent to the end of the fourth quarter, a DSMB held a second meeting to review VISTA-16 and recommended the study continue without modification. A DSMB meeting is scheduled to coincide with the upcoming biomarker analysis. Anthera will hold a conference call on February 28, 2011 to discuss the parameters and algorithm of the upcoming biomarker analysis, including the expected timeline for results.
- PEARL-SC resumed enrollment in Q4:10 after resolution of the vial fracture setback. Anthera's manufacturing partner, Merck BioManufacturing, has initiated pilot scale manufacturing of A-623 including the initial purification of intermediate products and small-scale fermentation. Anthera states that sufficient drug supply is on hand to complete PEARL-SC. Interim B-cell data for PEARL-SC is expected in mid-2011 and top-line data in 2012.

- Anthera has submitted a protocol (IMPACTS-2; 150 patient, placebo-controlled ACS prevention study in sickle cell patients) to FDA for A-001 based on promising data from a pre-specified interim review of a Phase II study (IMPACTS).

## Addendum

### STOCKS MENTIONED IN IMPORTANT DISCLOSURES

Ticker	Company Name
ANTH	Anthera Pharmaceuticals

### ANALYST CERTIFICATION

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

### IMPORTANT DISCLOSURES

Cowen and Company, LLC and or its affiliates make a market in the stock of ANTH securities.

Cowen and Company, LLC and/or its affiliates managed or co-managed a public offering of ANTH within the past twelve months.

Cowen and Company, LLC and/or its affiliates received in the past 12 months compensation for investment banking services from ANTH.

ANTH is or was in the past 12 months a client of Cowen and Company, LLC; during the past 12 months, Cowen and Company, LLC provided IB services.

ANTH has been client(s) of Cowen and Company, LLC in the past 12 months.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm's investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions.

### DISCLAIMER

This research is for our clients only. Our research is disseminated primarily electronically and, in some cases, in printed form. Research distributed electronically is available simultaneously to all Cowen and Company, LLC clients. All published research, including required disclosures, can be obtained on the Firm's client website, [www.cowenresearch.com](http://www.cowenresearch.com).

Further information on any of the above securities may be obtained from our offices. This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice.

**Notice to UK Investors:** This publication is produced by Cowen and Company, LLC, which is regulated in the United States by FINRA and is disseminated in the United Kingdom by Cowen International Limited ("CIL"). In the United Kingdom, 'Cowen and Company' is a Trading Name of CIL. It is communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without the consent of CIL.

#### Copyright, User Agreement and other general information related to this report

© 2011 Cowen and Company, LLC. Member NYSE, FINRA and SIPC. All rights reserved. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed,

in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research prior to any public dissemination by Cowen of the research report or information or opinion contained therein. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets). All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

**Cowen and Company, LLC. New York** (646) 562-1000 **Boston** (617) 946-3700 **San Francisco** (415) 646-7200  
**Chicago** (312) 516-4690 **Cleveland** (440) 331-3531 **Atlanta** (866) 544-7009 **Dallas** (214) 978-0107 **London**  
**(affiliate)** 44-207-071-7500 **Geneva (affiliate)** 41-22-707-6900

### COWEN AND COMPANY RATING DEFINITIONS (a)

Rating	Definition
Outperform (1)	Stock expected to outperform the S&P 500
Neutral (2)	Stock expected to perform in line with the S&P 500
Underperform (3)	Stock expected to underperform the S&P 500

(a) Assumptions: Time horizon is 12 months; S&P 500 is flat over forecast period.


### COWEN AND COMPANY RATING ALLOCATION (a)

Rating	Pct of companies under coverage with this rating	Pct for which Investment Banking services have been provided within the past 12 months
Buy (b)	49.5%	3.8%
Hold (c)	46.2%	1.5%
Sell (d)	4.3%	0.0%

(a) As of 12/31/2010. (b) Corresponds to "Outperform" rated stocks as defined in Cowen and Company, LLC's rating definitions (see above). (c) Corresponds to "Neutral" as defined in Cowen and Company, LLC's ratings definitions (see above). (d) Corresponds to "Underperform" as defined in Cowen and Company, LLC's ratings definitions (see above). Note: "Buy," "Hold" and "Sell" are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with NASD and NYSE regulations.

Cowen and Company Price and Ratings History

**Anthera Pharmaceuticals - ANTH**



Pricing data provided by Reuters America. Chart as of 2/22/11 in USD.